Growing evidence has revealed the close correlation of SETDB1 overexpression and abnormal activity in a variety of malignancies with an unfavourable prognosis of cancer patients (Figure 1) (Wong et al., 2016; Orouji et al., 2019; Yu et al., 2020; Strepkos et al., 2021). Here, SETDB1 is linked to cancer.